Andreas Rimner, MD

Articles by Andreas Rimner, MD

Andreas Rimner, MD, on Immunotherapy Combined with Radiation in Lung Cancer

November 25th 2019

The radiation oncologist from Memorial Sloan Kettering Cancer Center, discusses several ongoing trials combining immunotherapy and radiation at the 14th Annual New York Lung Cancers Symposium®.

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

ByJoe Yujiao Chang, MD, PhD,Larry L. Kestin, MD,R. Bryan Barriger, MD,Indrin J. Chetty, PhD,Mark E. Ginsburg, MD,Sanath Kumar, MD,Billy W. Loo, Jr, MD, PhD,Benjamin Movsas, MD,Andreas Rimner, MD,Kenneth E. Rosenzweig, MD,Thomas E. Stinchcombe, MD,Gregory M. M. Videtic, MD, CM,Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Latest Updated Articles

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
Published: August 15th 2014 | Updated:
Andreas Rimner, MD, on Immunotherapy Combined with Radiation in Lung Cancer
Published: November 25th 2019 | Updated:

Andreas Rimner, MD

Articles by Andreas Rimner, MD

Andreas Rimner, MD, on Immunotherapy Combined with Radiation in Lung Cancer

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care